This study is for people with a type of blood cancer called multiple myeloma, which has come back or doesn't respond to treatment. It tests two treatments: one with iberdomide and one without it. Iberdomide, daratumumab, and dexamethasone (IberDd) are compared to daratumumab, bortezomib, and dexamethasone (DVd). The goal is to see which treatment works better and is safer. In the first part, 200 people will try different doses of iberdomide. In the second part, around 664 people will be split into two groups to try one of the treatments.
- The study lasts until the disease gets worse or side effects are too strong.
- Participants must have multiple myeloma and have tried 1-2 treatments before.
- The study follows strict international research rules to protect participants.
How understandable was the trial content above?
Hard to understand
Easy to understand